Nimodipine Suppliers & Bulk Manufacturers

Available Forms: Tablet/ Injection

Available Strengths: 30 mg

Reference Brands: Nimotop (USA)

Category: Neurology

Nimodipine is available in Tablet/ Injection and strengths such as 30 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Nimodipine is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Nimodipine can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Nimodipine is a second-generation 1,4-dihydropyridine calcium channel blocker that was initially approved for the management of hypertension. In current clinical practice, it is primarily used to prevent and manage cerebral vasospasm following subarachnoid hemorrhage, a condition that can lead to severe neurological complications. Nimodipine acts by selectively blocking calcium channels in cerebral blood vessels, resulting in vasodilation and improved cerebral blood flow, which helps reduce the risk of ischemic brain injury.

Nimodipine is available in multiple dosage forms, including oral capsules, oral solutions, and intravenous infusions, allowing flexibility in administration based on patient condition and clinical setting. Its ability to cross the blood–brain barrier makes it particularly effective in targeting cerebral vasculature. In addition to its approved indication, nimodipine has been explored for off-label uses in various neurological conditions.

Appropriate administration of nimodipine requires careful consideration of dosing schedules, contraindications, and potential adverse effects such as hypotension, headache, and gastrointestinal disturbances. Continuous monitoring by healthcare professionals is essential to optimize therapeutic outcomes and minimize risks. Proper understanding of nimodipine’s pharmacology supports effective treatment and improved patient outcomes in subarachnoid hemorrhage management.